Viehbacher's supposed failings: from Brazil to Phoenix via Lantus
This article was originally published in Scrip
It wasn't because he wasn't French enough: failings in execution and communication with the board led to his departure. That is the essence of the message coming from Sanofi over the shock sacking of its CEO Chris Viehbacher by the unanimous decision of its board of directors. The removal was precipitated by media leaks, but had been under consideration since the summer, the company confirmed.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.